Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (1y) (2011 - 2025)
Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.39 Bn | 30.45 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.59 Bn | 23.53 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.46 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 18.00 Bn | 16.69 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -21.54% |
| 10 | Biocryst Pharmaceuticals | 2.37 Bn | 2.31 Bn | 151.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -135.63% |
| Sep 30, 2025 | 32.96% |
| Jun 30, 2025 | 554.89% |
| Dec 31, 2024 | 72.18% |
| Sep 30, 2024 | -54.51% |
| Jun 30, 2024 | -150.32% |
| Mar 31, 2024 | 46.88% |
| Dec 31, 2023 | -406.84% |
| Sep 30, 2023 | 464.00% |
| Jun 30, 2023 | 91.39% |
| Mar 31, 2023 | -60.59% |
| Dec 31, 2022 | -52.53% |
| Sep 30, 2022 | -52.05% |
| Jun 30, 2022 | -69.99% |
| Mar 31, 2022 | 310.10% |
| Dec 31, 2021 | 614.84% |
| Sep 30, 2021 | 112.21% |
| Jun 30, 2021 | 1,045.07% |
| Mar 31, 2021 | -14.66% |
| Dec 31, 2020 | 93.75% |